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ABSTRACT

SQUAMOUS CELL CARCINOMA RESPOSNE TO CISPLATIN EXPSOURE
Khanh V. Luong, D.D.S
University of Nebraska, 2015
Advisor: Aimin Peng, Ph.D.
Purpose: This thesis attempted to quantitatively analyze the individual cell
fate choice in resistant head and neck UM-SCC38 cells exposed to cisplatin
using the most current techniques available.
Methods: UM-SCC-38 cells were grown in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine serum (FBS). They were
treated with cisplatin and ATM/ATR inhibitors of known dosages. Using live cell
imaging, one hundred cells were tracked in each experiment and their behaviors
were analyzed and entered into Microsoft Excel Spreadsheet to generate cell
profile graphs. HaCaT cells, non-tumorigenic keratinocyte cell line, were also
analyzed using live cell imaging and their cell fate profiles generated to better
understand the resistance of SCC-38 to cisplatin.
Results: Our study revealed a highly heterogeneous pattern of cell fate
choices in SCC-38, in comparison to that of the control, HaCaT, cells. In both
SCC-38 and HaCaT cell lines, the majority of cell death occurred in the
immediate interphase without mitotic entry, whereas significant portions of SCC38 cells survived the treatment via either checkpoint arrest or checkpoint
slippage. Cells that exhibited checkpoint slippage were primarily treated or

vii
exposed to cisplatin at late-S and G2 phases. Our study also revealed cells in Mphase were hypersensitive to cisplatin. Moreover, although the cisplatin resistant
progression of mitosis exhibited no delay in general, greatly prolonged mitosis
correlated with the induction of cell death in mitosis. This finding suggested a
combinatorial treatment using cisplatin and an agent that blocks mitotic exit, Mg132. Consistently, we showed a strong synergy between cisplatin and the
proteasome inhibitor Mg-132. Finally, targeting DNA damage checkpoint using
ATR inhibitor effectively sensitized SCC-38 to cisplatin treatment. To our
surprise, targeting checkpoint eliminated both checkpoint arrest and checkpoint
slippage, and augmented the induction of cell death in interphase without mitotic
entry.
Conclusion: The diverse cell fate choices of SCC-38 and HaCaT cells
were confirmed using live cell imaging. Our results showed the majority of cell
death occurred in interphase without mitotic entry and a significantly smaller
portion of SCC-38 cells died after the cisplatin treatment when compared to
HaCaT. On the other hand, analysis of the surviving SCC-38 cells revealed the
co-existence of checkpoint arrest and checkpoint slippage. However, caffeine
was shown to abolish these surviving mechanisms in cisplatin treated cells.
Moreover, our combination therapy of cisplatin plus MG-132 showed strong
synergistic effect on SCC-38 cell death. Overall, our study revealed new insights
into chemoresistance and suggested combinatorial strategies that potentially
overcome cancer resistance.
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CHAPTER 1: INTRODUCTION

Squamous cell carcinoma (SCC) of the head and neck is the sixth most
common malignancy in the world today (Lingen et al 2010). The etiology is multifactorial and site-specific. For instance, oral cavity SCC has long been
associated with tobacco and alcohol abuse. Despite numerous advances in
early cancer detection, prevention, and treatment, the overall 5-year survival
remains modest at best (Lingen et al 2010).
At the molecular level, cancer is characterized as genetic alterations to
individual cells, leading to cellular functions such as resistance to cell death,
increased cell proliferation, and the ability to invade and metastasize (Teng
2015). To combat such tumorigenic cellular behaviors, genotoxic agents are
designed to induce apoptosis and other cell death pathways by causing DNA
damage (Jackson, 2009). Cancer cells can be particularly vulnerable to DNA
damage as they actively undergo DNA replication and cell proliferation. However,
the therapeutic benefit of chemotherapy is limited in many clinical cases due to
intrinsic or acquired resistance of tumor cells to DNA damage. Thus, it has been
suggested that targeting the cellular DNA damage response (DDR) may offer a
valuable tool to improve the therapeutic window and effectiveness of
chemotherapy (Bolderson et al 2009, Al-Ejeh et al 2010).
Among the most successful and commonly used chemotherapeutic drugs
are cisplatin (cis-diamminedichloroplatinum) and other platinum-based drugs.
Cisplatin was first approved by the FDA in 1978 for the treatment of testicular
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and bladder cancer (Galluzzi et al 2011). Over the past decades, cisplatin and its
variants have been prescribed for an estimated 10 to 20 percent of all cancer
patients. The use of cisplatin in the treatment of testicular cancer improved the
cure rate from 10% to 80%. Today, cisplatin is broadly used for a wide range of
other solid tumors, including those of lung, breast, ovarian, head and neck, etc.
However, the efficacy of cisplatin in these other solid tumors appears less
satisfactory, as many tumors either exhibit intrinsic resistance to cisplatin or
relapse despite initial response (Galluzzi et al 2011, Caponigro et al 2006).
Like other genotoxic drugs or radiation, cisplatin exerts cytotoxicity by
inducing DNA damage. Specifically, cisplatin binds DNA and cause DNA inter- or
intra-strand crosslinking, a form of DNA damage that blocks DNA replication and
transcription (Galluzzi et al 2011, Caponigro et al 2006). The occurrence of DNA
damage quickly activates the DDR, a conserved mechanism evolved in
eukaryotic cells to govern genomic integrity. The DDR encompasses various
lesion specific DNA repair pathways, and a sophisticated signaling network that
activates the cell cycle checkpoint and cell death (Zhou 2000, Jackson 2009). At
the center of the molecular pathway of the DDR are the phosphoinositide 3kinase-related kinases (PIKK) ATM and ATR. Activation of ATM and ATR by
DNA damage in turn results in phosphorylation of dozens of physiological
substrates that control various pathways including DNA repair, checkpoint
control, and apoptosis (Shiloh 2003). For example, ATM and ATR activate the
checkpoint kinases Chk1 and Chk2, which phosphorylate and inactivate Cdc25,
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an activator of cyclin-dependent kinases (Cdks), and thereby preventing Cdk
activation and cell cycle progression (Sancar et al 2004).
The ultimate result of the DDR can be either cell survival or cell death, and
the choice between them may essentially dictate the outcome of cancer therapy.
In fact, several distinct cell fate choices should be considered. First, cell death
can be induced as the desired outcome that leads to therapeutic benefit.
Alternatively, the cell may cease proliferation via sustained activation of the DNA
damage checkpoint, a state described as senescence. Although this cell fate
choice halts the growth of tumor cells, these cells may re-enter the cell cycle
progression after acquiring additional changes. Finally, and perhaps of the worst
possibility, cancer cells may continue cell proliferation despite the treatment.
In this study we use automated time-lapse microscopy to quantitate the profile of
cell fate determination in resistant cancer cells treated with cisplatin. Our study
revealed heterogeneous and complex pattern of cell fate determination in these
cancer cells. The results suggested the potential cause of cell protection via both
checkpoint activation and checkpoint slippage. More interestingly, our analyses
revealed new insights into how targeting mitotic exit and the DNA damage
checkpoint can alter the pattern of cell fate choices and enhance the treatment
efficacy.
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CHAPTER 2: LITERATURE REVIEW

2.1 DNA Damage Response (DDR) Pathways

Each cell in the human body is under constant threat to DNA lesions from
both the endogenous and environment agents. The most pervasive
environmental DNA-damaging agent is UV light from the sun, which can induce
~100,000 lesions per exposed cell per hour (Jackson 2009). Other common
forms of environmental DNA-damaging agent are ionizing radiation and tobacco
products. Ionizing radiation can cause double-strand breaks (DSBs), while
tobacco products can trigger various cancers, most notably those of the lung and
oral cavity (Jackson 2009). Metabolic products such as reactive oxygen species
also present challenge to the genomic stability. While the prime objective of each
cell is to deliver its genetic material, intact and unchanged, to the next
generation, the DNA damage incurred by each cell must be repaired to prevent
incorrect transmission of the genetic material. To counter both the endogenous
and environmental threats, cells have evolved an intricate series of mechanisms
to first, detect DNA damage, second, to accumulate DNA repair factors and third,
physically repair the lesion (Zhou 2000). Collectively, these mechanisms are
known as the DNA damage response (DDR). In general, DDR can be divided
into distinct pathways based on the type of DNA lesion they process. For
example, simple DNA changes, such as oxidative lesions and single-strand
breaks (SSBs), are repaired through a mechanism called base excision repair
(BER); while major mechanisms that cope with double-strand breaks (DSBs) are
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homologous recombination and non-homologous end joining (NHEJ) (Lord
2012). The ultimate results of the DDR can either be cell survival or control cell
death. If the cell successfully repairs DNA damage, it would turn off the DDR
and return to normal cell proliferation; likely wise, if the damage cannot be
removed, chronic DDR signaling triggers cell death by apoptosis. However, if the
DNA repair mechanism fails, three possible fates are ensured: (1) senescence,
(2) apoptosis, and worst of all (3) tumor formation.
2.2 Cisplatin and Its Molecular Mechanisms

Platinum-based drugs are best known for treatment of various solid
tumors, including testicular, ovarian, head and neck, colorectal, bladder and lung
cancers (Galluzzi et al 2011). Cis-diammineplatinum (II) dichloride (best known
as cisplatin) was first approved by the FDA in 1978 for the treatment of testicular
and bladder cancer (Galluzzi et al 2011). Today, cisplatin is a largely employed
platinum-based compound for the treatment of wide spectrum of solid
neoplasms, such as testicular, bladder, ovarian, colorectal, lung and head and
neck cancers (Toulany et al 2014). Despite positive initial responses, many
cancer patients eventually develop chemoresistance to cisplatin-based therapies,
leading to relapse and therapeutic failure. High incidence of chemoresistance is
cited as the main clinical limitation to the usefulness of cisplatin (Toulany 2014).
Therefore, circumventing cisplatin resistance is a critical goal for anticancer
therapy and considerable efforts have been undertaken to solve this problem
throughout the past decades.
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The detailed description of the molecular mechanism of cisplatin can be
found elsewhere (Sanderson et al 1996, Siddik 2003). In general, cisplatin exerts
its anticancer effects via a complex signaling pathway. Upon cellular absorption
and processing, cisplatin must be intracellularly activated by a series of reactions
that consist of substituting one or both cis-chloro groups with water molecules
(Sanderson et al 1996). Equated cisplatin is active and can cause significant
damages to both the cytoplasm and nucleus. In the nucleus, cisplatin avidly
binds to DNA and causes DNA strand cross-linking. Such distortions in the DNA
can be recognized by multiple repair pathways (Siddik 2003). The major
signaling network that senses DNA lesion is the DNA damage response (DDR)
as discussed above.
2.3 DNA Damage Checkpoints

Cell cycle checkpoints are control mechanisms composed of signaling
pathways that control the ability of cells to arrest the cell cycle in response to
DNA damage, allowing time for repair. Moreover, it controls the activation of DNA
repair pathways and the movement of DNA repair proteins to sites of DNA
damage (Zhou 2000).
The recognition of DNA lesions involves the sequential activation of DNA
damage sensors, transducers, and effectors. The ataxia telangiectasia mutated
(ATM) and RAD3-related protein (ATR) are important sensors of the DNA
damage and have been shown to participate in cisplatin-induced DNA damage.
Activation of ATM and ATR leads to downstream phosphorylation of various
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physiologic substrates (Wang et al 2012). For instance, ATM and ATR activate
checkpoint kinase 1 (Chk1, the most prominent substrate and effector of ATR)
and checkpoint kinase 2, respectively. Chk1 and Chk2 then phosphorylate and
inactivate Cdc25, an activator of cyclin-dependent kinases (Cdks), and thereby
preventing Cdk activation and cell cycle progression. In addition, activated ATM
and ATR also phosphorylate H2AX at the site of DNA damage, which recruits a
number of DDR factors to facilitate DNA repair and checkpoint signaling (Wang
et al 2012).
Despite similarity in functions, ATM and ATR are activated through
different mechanisms. Mre11-Rad50-Nbs1 complex is the primary sensor of
double strand breaks (DSBs). It migrates rapidly to the sites of DMA damage to
form nuclear foci and facilitates the recruitment of ATM (Hurley and Bunz 2007).
ATR, on the other hand, functions as a sensor for single strand DNA (ssDNA)
damage (Hurley and Bunz 2007).
2.4 Caffeine and Its Molecular Mechanism

Caffeine is a popular central nervous system (CNS) stimulant and
commonly used as a stimulant to prevent sleepiness. It is found in coffee, tea,
cola nuts, and cocoa. For many years, caffeine has been generally believed to
suppress cell proliferation, abolish cell cycle progression and enhance the toxicity
of radiation and anticancer agents (Bode and Dong 2007). Specifically, caffeine
has been reported to induce G1/S arrest and to reverse the G1/S and G2/M
checkpoint delay periods. Importantly, when caffeine is combined with DNA-
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damaging agents, the potency of the DNA-damaging agent is increased
markedly (Bode and Dong 2007). Many studies suggested that the increased
toxicity of chemical agents is associated with caffeine’s inhibition of the G2
checkpoint activity, which would accelerate movement of the cell cycle through
the G2/M checkpoint, thus leaving cells less time to repair DNA damage and
eventually lead them to apoptosis.
The cellular effects of caffeine resemble some defects observed in ataxia
telangiectasia (AT) cells. Current studies support the evidence that ATM and
ATR are primary targets of caffeine (Bode and Dong 2007). ATM and ATR
belong to the phosphatidylinositol-3 kinase (PI-3 kinase) and caffeine has been
shown to inhibit various forms of PI-3 kinase. Moreover, caffeine also target
protein p53, a tumor suppressor protein that is believed to be the primary
mediator of cell cycle arrest and induction of apoptosis in most cell lines in
response to DNA damage.
2.5 KU55933 and Its Molecular Mechanism

KU-55933 has recently been discovered and is found to have great
selectivity for ATM that is 100-fold greater than other related kinases. Studies
have shown that KU-55933 induces cell cycle arrest at the G1 phase and leads to
apoptosis under serum starvation conditions (Li and Yang 2010).
2.6 VE-821 and Its Molecular Mechanism
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VE-821 is a potent and competitive inhibitor of ATR. Inhibition of ATR led
to inhibition of DNA-damage-induced G2/M arrest in cancer cells. Treatment of
cancer cells with anticancer agents along with VE-821 has shown to increase
DNA damage and inhibit homologous recombination repair (Prevo et al 2012).
This evidence suggests that ATR inhibition with VE-821 is a novel approach to
cancer therapy. VE-821 along with cisplatin treatment shows marked synergy
(Prevo et al 2012).
2.7 MG-132 and Its Molecular Mechanism

MG-132 is a proteasome inhibitor. It has been shown to inhibit cellular
proliferation and induce cell death in esophageal squamous cell carcinoma
(Crawford et al 2006). MG-132 induces apoptosis through the activation of class
III PI3K pathway and the release of caspase-3.
2.8 UM-SCC-38 Cells

UM-SCC-38 cell line was obtained from Dr. Thomas E. Carey (University
of Michigan, Ann Arbor). The cells were originated from a tissue sample of a 60year-old patient with squamous cell carcinoma of the oropharynx. Previous study
by Wang et al (2012) showed that among the UM-SCC cell lines, SCC-38 was
most resistant to cisplatin. Therefore, we determine it would be most ideal to
study the behavior of SCC-38 to cisplatin in adjunct with other agents/inhibitors.
2.9 HaCaT Cells

10

HaCaT cells are immortalized, non-tumorigenic human keratinocyte.
HaCaT cells have been shown to be much more sensitive to cisplatin treatment
compared to SCC-38 (Wang et al 2012). For this reason, we will use HaCaT cells
as control for our experiment.
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CHAPTER 3: MATERIALS AND METHODS

3.1 Cell culture

The oral squamous cell carcinoma cell line, UM-SCC-38, was obtained
from Dr. Thomas Carey (University of Michigan, Ann Arbor, MI.) and cells were
grown in Dulbecco’s modified Eagle’s medium (DMEM, Sigma Chemical Co., St.
Louis, MO.) supplemented with 10% fetal bovine serum (Hyclone Laboratories,
Logan, UT). They were incubated in a humidified atmosphere of 5% CO2 at 37o

C. HaCat cells were obtained from Dr. Pam Jensen (University of Pennsylvania,

Philadelphia, PA.) and were passaged using DMEM medium lacking calcium
(Invitrogen, Grand Island, NY.) supplemented with 10% fetal bovine serum.
Unless specified, prior to each live cell microscopy cells were transferred to a 6well plate (CELLTREAT Scientific Products, Shirley, MA) and grown in DMEM
medium for 24 hours prior to treating with appropriate drug or inhibitor
concentrations.
3.2 Cisplatin preparation

Cisplatin was purchased in powder form, cis-diammineplatinum (II)
dichloride (Sigma, St. Louis, MO). Cisplatin has a molecular weight of 300.01
g/mol. The stock solution was prepared in purified water (ddH2O) to 3 mM and
kept in -20oC environment. A new bath of 3 mM stock solution was prepared
every 6 months to avoid any potential long-term changes to the structures of the
complex. Unless specified, cisplatin was used at a final concentration of 16 µM
throughout this entire experiment.
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3.3 Inhibitor preparation

The following inhibitors were used: caffeine (Sigma, St. Louis, MO), KU
55933, an ATMi inhibitor (EMD Chemicals), VE-821, an ATRi inhibitor (SELLECK
Chemical LLC) and Mg-132, a proteasome inhibitor (Sigma, St. Louis, MO).
Caffeine (anhydrous) has a molecular weight of 194.2 g/mol. Caffeine stock
solution was prepared in purified water (ddH2O) to 100 mM. KU 55933, VE-821
and Mg-132 were all purchased in power form and dissolved in DMSO to make a
stock solution of 5 mM, 10 mM and 100 mM, respectively. All inhibitors were
stored and kept in -20oC environment. The final concentrations of these
inhibitors were obtained from the literatures and they are 4 mM for caffeine, 20
µM for KU-55933, 10 µM for VE-821, and 5 µM for Mg-132 (Ashley et al 2014).
3.4 Pilot study design
3.4.1 Determining the best cisplatin concentration

The purpose of the pilot study was to determine the best dose and
timeframe to study cell death. Two days prior to live cell microscopy cells were
passaged and seeded in a 24-well plate (CELLTREAT Scientific Products,
Shirley, MA) at roughly 50 to 80% confluence. Each well contained 1 mL DMEM
and the plate was incubated at 37oC for 24 hours. On the next day cells were
treated at four different cisplatin concentrations: 4 µM, 8 µM, 16 µM, and 32 µM
(Fig. 3.4.1). The plate was incubated again for another 24 hours. The following
observations were made after 24 hours: almost all cell death were observed in 32
µM wells, minimal to no cell death at 4 µM wells and roughly 50% cell death
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observed at 16 µM wells. Therefore, we decided 16 µM cisplatin would be the
optimal cisplatin concentration to study cell death.
3.4.2 Does caffeine alone have any effect on cell behavior?

To ensure that caffeine alone does not have significant effect on cell
behavior, we performed a pilot study of caffeine treatment. Similar to cisplatin
setup above, UM-SCC-38 cells were seeded in a 6-well plate. It was incubated at
37oC for 24 hours. On the second day, only caffeine (4 μM) was added to the
experimental well (Figure 3.4.2). However, instead of tracking cell behavior under
the time lapse microscope, we incubated the plate again for another 24 hours.
The cells were observed under the light microscope and an image was taken to
capture the post-caffeine cell population as well as the control group (Figure
4.5.4). Clearly, caffeine alone did not show any significant effect on cell death
compared to the control group.
3.5 Time Lapse Experiment and Study Design
3.5.1 Cisplatin Only
One day prior to time lapse microscopy, UM-SCC-38 cells were seeded in
a 6-well plate at roughly 80% confluence. Each 35-mm well contained 2.5 mL
DMEM solution. The plate was then incubated at 37oC for 24 hours. Twenty-four
hours later, cisplatin was added to the experimental well. The control well was
imaged without any drug to serve as control. The amount of drug was calculated
based on the amount of solution in the well and the desired drug concentration.
For example, 16 µM cisplatin in 2.5 mL solution is calculated as follow:
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𝑎𝑚𝑡. 𝑜𝑓 𝑐𝑖𝑠𝑝𝑙𝑎𝑡𝑖𝑛 𝑛𝑒𝑒𝑑𝑒𝑑 (µ𝐿) =
16µ𝑚𝑜𝑙
𝐿

2.5 𝑚𝑙
𝐿
1000𝑚𝐿
𝐿
300µ𝑚𝑜𝑙

16µ𝑚𝑜𝑙
𝐿

𝑥

2.5 𝑚𝑙

𝐿

𝐿

𝑥 1000𝑚𝐿 𝑥 300µ𝑚𝑜𝑙 𝑥

106
𝐿

= 133.3µ𝐿

= 𝑑𝑒𝑠𝑖𝑟𝑒𝑑 𝑐𝑖𝑠𝑝𝑙𝑎𝑡𝑖𝑛 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
= 𝑣𝑜𝑙𝑢𝑚𝑒 𝑖𝑛 𝑒𝑎𝑐ℎ 𝑤𝑒𝑙𝑙
= 𝑐𝑜𝑛𝑣𝑒𝑟𝑠𝑖𝑜𝑛 𝑢𝑛𝑖𝑡
= 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑐𝑖𝑠𝑝𝑙𝑎𝑡𝑖𝑛 𝑠𝑡𝑜𝑐𝑘 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛

Unless specified, the amount of cisplatin remained constant through this entire
experiment. The plate was then loaded into Zeiss time-lapse microscope for 24hour imaging. Figure 3.5.1 illustrates cisplatin study design.
3.5.2 Cisplatin and MG-132

All procedures all similar as mentioned above. The design is illustrated in
figure 3.5.2. The amount of MG-132 was calculated as follow:
𝑎𝑚𝑡. 𝑜𝑓 𝑀𝐺132 𝑛𝑒𝑒𝑑𝑒𝑑 (µ𝐿) =

5µ𝑚𝑜𝑙
𝐿

𝑥

2.5 𝑚𝑙

𝐿

𝐿

𝑥 1000𝑚𝐿 𝑥 1000µ𝑚𝑜𝑙 𝑥

106
𝐿

= 12.5µ𝐿

3.5.3 Cisplatin and Caffeine

The study design for cisplatin and caffeine is illustrated in figure 3.5.3. The
amount of caffeine was calculated as follow:
𝑎𝑚𝑡. 𝑜𝑓 𝑐𝑎𝑓𝑓𝑒𝑖𝑛𝑒 𝑛𝑒𝑒𝑑𝑒𝑑 (µ𝐿) =

4𝑚𝑚𝑜𝑙
𝐿

𝑥

2.5 𝑚𝑙

𝐿

𝐿

𝑥 1000𝑚𝐿 𝑥 100𝑚𝑚𝑜𝑙 𝑥

106
𝐿

= 100µ𝐿

3.5.4 Cisplatin and ATMi/ATRi

The study design for cisplatin and ATMi/ATRi is illustrated in figure 3.5.4.
The amounts of KU-55933 and VE-821 are calculated as follow:
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𝑎𝑚𝑡. 𝑜𝑓 𝐾𝑈 − 55933 𝑛𝑒𝑒𝑑𝑒𝑑 (µ𝐿) =
𝑎𝑚𝑡. 𝑜𝑓 𝑉𝐸 − 821 𝑛𝑒𝑒𝑑𝑒𝑑 (µ𝐿) =

20µ𝑚𝑜𝑙
𝐿

10µ𝑚𝑜𝑙
𝐿

𝑥

𝑥

2.5 𝑚𝑙

2.5 𝑚𝑙

𝐿

𝑥 500µ𝑚𝑜𝑙 𝑥
𝐿

106 µ𝐿

𝐿

𝐿

𝑥 1000𝑚𝐿 𝑥 100µ𝑚𝑜𝑙 𝑥

= 100µ𝐿
-106
𝐿

= 250µ𝐿

3.5.5 Live cell microscopy and cell imaging analysis

Immediately after drug/inhibitor addition, live cell imaging was performed
using a Zeiss Microscope with Marianas Software (Intelligent Imaging
Innovations, Inc. Denver, CO.), with images collected at 10X objective every 10
minutes for 24 hours. Image sequences were viewed using Slidebook Reader 5.5
(Intelligent Imaging Innovations, Inc. Denver, CO.). Once the live cell microscopy
was completed, the captured images were loaded into SlideBook Reader
Software (3i, Denver, CO). In each well one hundred cells were tracked for cell
fates (Figure 3.5.5).
3.6 Graphs Generation

Cell behaviors were recorded manually and entered into Microsoft Excel
Spreadsheet to generate cell profile graphs (Figure 3.6).
3.7 Statistical Analysis
Statistical significance was analyzed using an unpaired 2-tailed Student’s
t-test. The values are presented as the means ± standard errors. A P-value <0.05
was considered statistically significant.
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Figure 3.3.1. Pilot study design
SCC-38 cells were treated with 16 different combinations of cisplatin
concentration and cellular confluence. Each well contained 1 mL DMEM
solution. Left column contained SCC-38 cells without cisplatin treatment to serve
as control.

Figure 3.3.2. Caffeine only study design
SCC-38 cells were treated with or without 4 mM caffeine only.
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Figure 3.5.1. Preparing for cisplatin time-lapse experiment
SCC-38 cells were seeded in 6-well plate. They were treated with or without 16
µM cisplatin.

Figure 3.5.2. Preparing for cisplatin-Mg-132 time-lapse experiment
SCC-38 cells were treated with cisplatin alone or cisplatin plus Mg-132
combination.
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Figure 3.5.3. Preparing for cisplatin-caffeine time-lapse experiment
SCC-38 cells were treated with cisplatin alone or cisplatin plus caffeine
combination

Figure 3.5.4. Preparing for cisplatin-caffeine time-lapse experiment
SCC-38 cells were treated with cisplatin alone, cisplatin-KU55933 or cisplatinVE-821 combination.
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Figure 3.5.5. SCC-38 cell labeling
This image illustrates a time-lapse image with one hundred SCC-38 cells labeled.
Each cell was tracked for their behavior during the entire 24-hour experiment.

Figure 3.6. Recorded SCC-38 cell behavior
This image provides an example of recorded cell behavior. The data were
entered into Microsolf Excel to generate figure profiles.
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CHAPTER 4: RESULTS

4.1 Chemoresistant cancer cells display diverse fate profiles

As discussed in our literature review section, SCC-38 cell line was
selected because this head and neck squamous cell carcinoma (HNSCC) has
been previously characterized to be resistant to cisplatin treatment (Wang et al
2012, Brenner 2010). To shed new light on cisplatin resistance, live cell imaging
was utilized to determine the initial fate of UM-SCC38 cells after cisplatin
exposure (Fig. 4.1.1, Fig. 4.1.2). Cell profiles from six consecutive experiments
show consistent results: the vast majority of unperturbed SCC-38 cells
underwent normal cell division, while a dramatically different cell fate profile
existed in the presence of cisplatin (Fig. 4.1.3). As expected, a significant
induction of cell death was observed in cells exposed to cisplatin, 60% compared
to 15% cell death in untreated sample (Table 4.1). Cell death was further
investigated for the cell cycle stage in which it occurred. For example, death in
interphase defined those cells that died in the immediate interphase without
mitotic entry; death in mitosis characterized those that entered mitosis and died
during mitosis; and finally, some cells died in the second interphase after mitotic
entry and exit. As evident in Figure 4.1.4, the majority of cell death (45%)
induced by cisplatin occurred in interphase without mitotic entry. A moderate
increase (13%) was documented in cell death in interphase after the first mitosis,
but no increase was seen in the portion of mitotic cell death (Fig. 4.1.4).
Therefore, although mitotic cell death has been implicated in chemotherapy, e.g.
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via mitotic catastrophe, it did not appear to play a significant role in the treatment
of cancer cells with cisplatin.
Consistent with the previously characterized chemoresistance of SCC-38 cells,
significant portions of cells (40%) survived the treatment. As shown in Figure
4.1.5, cisplatin induced DNA damage checkpoint was evidenced by
approximately 25% of cells remained in the interphase throughout the 24-hour
period, compared to 2% in the drug-free group. The activation of DNA damage
checkpoint after cisplatin treatment was consistent with previous study (Galluzzi
et al 2011; Prendergast et al 2011; Pabla et al 2008). Moreover, an average 14%
of cells underwent continuous cell cycle progression despite cisplatin treatment.
Thus, this portion of cells escaped the induction of cell death and checkpoint
arrest (Fig. 4.1.6). This cell fate choice is classified here as “checkpoint
slippage”, as also implicated in previous studies (Shaltiel et al 2015, Bartek et al
2007, Clemenson et al 2009, Syljuasen 2007). The nature of checkpoint slippage
is not fully understood at the present moment. In principle, the deficiency of
checkpoint activation can lead to continued cell division after DNA damage.
Alternatively, the checkpoint may be initially activated but de-activated
subsequently due to DNA repair, or hyperactivation of checkpoint recovery or
adaptation mechanisms (Clemenson et al 2009, Syljuasen 2007, Peng 2013)
Interestingly, cells in the group of checkpoint slippage entered mitosis in
approximately 3.5 hours after cisplatin-treatment (Fig. 4.1.7). By comparison,
mitotic entry in unperturbed cells took 7 hours in average (Fig. 4.1.7). We
speculated that the difference in the timing of mitotic entry reflected a cell cycle-
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dependence of checkpoint slippage. For example, cells slipped into mitosis were
exposed to cisplatin in late S and G2 phases, whereas cells treated in G1 and
early S phases was effectively prevented from mitotic entry due to checkpoint
arrest or cell death. There are several possible mechanisms underlying this
observation. First, induction of DNA damage by cisplatin may be less efficient in
late S and G2 cells, or alternatively, the DNA damage checkpoint in late S and
G2 is inadequate in preventing mitotic entry. Notably, previous studies indicated
that an imperfect G2/M DNA damage checkpoint failed to halt the cell cycle with
a subthreshold level of DNA damage (Deckbar et al 2007; Krempler et al 2007).
4.2 Duration of mitotic arrest does not dictate cell fate

Mitotic arrest can result from erratic progression of mitosis and activation of the
mitotic spindle checkpoint. Surprisingly, no mitotic arrest was induced by cisplatin
treatment, as cells in the control and cisplatin-treated groups spent similar
amount of time in mitosis, 43 minutes and 40 minutes, respectively (Fig. 4.2.1).
We further separated the cisplatin-treated and mitotic-entering cells into three
groups based on their subsequent cell fate: died in mitosis, exited mitosis and
survived, or exited mitosis and died in the following interphase (Fig. 4.2.2). We
observed no correlation between mitotic duration and the subsequent cell fate
after mitotic exit (Fig. 4.2.2). Therefore, we concluded mitotic duration does not
predict cell death or survival in the subsequent interphase. However, dramatically
prolonged mitosis was associated with mitotic death, as cells that destined to die
in mitosis spent an average of 126 minutes in mitosis before undergoing
apoptosis (Fig. 4.2.2). This finding suggested delaying mitotic exit may enhance
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the effectiveness of cisplatin by inducing cell death in mitosis. To directly test this
hypothesis, we co-treated SCC-38 cells with Mg-132, a proteasome inhibitor
known to suppress M-phase exit (Skoufias et al 2007). Very surprisingly, the
combination of cisplatin and Mg-132 caused 96% mitotic cell death, compared to
less than 4% with cisplatin alone (Fig. 4.2.3). Similarly, the finding was confirmed
in Dr. Peng’s lab with cell proliferation and clonogenic assays (Fig. 4.2.4, Fig.
4.2.5).
4.3 SCC-38 M-phase cells are hypersensitive to cisplatin

As we understood, cisplatin induced cell death by causing DNA crosslinking, the
process that interferes with DNA replication and transcription (Galluzzi et al 2011;
Caponigro et al 2006). Moreover, recent studies revealed that mitotic DNA
damage responded differently from that of interphase cells; it is often diminished
(Heijink et al 2013; Giunta et al 2010). Hence, this knowledge prompted us to
examine the fate of cells exposed to cisplatin during mitosis, a cell cycle stage in
which DNA replication and transcription are suppressed. Figure 4.3.1 represents
a collection of M-phase cells that were exposed to cisplatin from all of our
experiments. Similar to interphase cells, M-phase cells exhibited multiple fates
following cisplatin exposure (Fig. 4.3.1). However, M-phase cells were extremely
sensitive to cisplatin, and the chance of cell survival was markedly reduced in
cells exposed to cisplatin in mitosis: 7% survival in M-phase compared to 44% in
interphase (Fig. 4.3.2). Of the 93% of M-phase cells died after cisplatin
treatment, 34% died during mitosis and the other 59% completed cell division,
and then died in the subsequent interphase (Table 4.3). Furthermore, 29% of
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cells died in early mitosis prior to any sign of cell division, whereas 5% cells
death occurred in late stages of mitosis. In light of these results, we concluded
that 1) cisplatin exerted cytotoxicity in mitotic cells independent of DNA
replication and transcription, and 2) cisplatin induced cell death in mitotic cells
with a much higher potency compared to that in interphase cells.
4.4 Chemoresistant cells are protected from cell death by both checkpoint
arrest and slippage

To better understand the cisplatin resistance of SCC-38 cells, we comparatively
analyzed the cell fate profile of HaCaT, a spontaneously transformed
keratinocyte cell line known to be cisplatin-sensitive (Wang et al 2012). Cell
profiles of SCC-38 and HaCaT being treated with cisplatin are shown in Figure
4.4.1. Evidently, marked difference in cell fate profiles was noticed between
cisplatin-treated SCC-38 and HaCaT cells. As expected, cisplatin induced cell
death more efficiently in HaCaT cells (Fig. 4.4.1). Approximately 88% of HaCaT
cells died in interphase compared to 45% of SCC-38 cells (Fig. 4.4.2). By
comparison, cell death in mitosis or cell death in interphase after the first mitosis
was not increased, but rather moderately reduced in HaCaT cells (Fig. 4.4.2).
Importantly, and in sharp contrast to SCC-38 cells, HaCaT cells exhibited much
less checkpoint activation and checkpoint slippage in response to cisplatin. Only
4% HaCaT cells remained arrested in interphase in comparison to 28% in SCC38; and 1% of HaCaT cells underwent continued cell cycle progression in the
presence of cisplatin, compared to 11% of SCC-38 cells (Fig. 4.4.3). This
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comparative study of cell fate profiles underlied the critical role of both checkpoint
activation and slippage in protecting cells from cell death, which may
subsequently lead to cancer resistance.
4.5 Caffeine sensitizes cell death by abolishing both checkpoint activation
and checkpoint slippage

It has been suggested that targeting the cellular DDR mechanism rendered cell
defenseless. We thought this process would make cancer cells more susceptible
to radiation and chemotherapy. For example, it is typically thought that disruption
of the DNA damage checkpoint will allow cell cycle progression after DNA
damage. And subsequently, cell division with unrepaired DNA damage leads to
further accumulation of DNA damage, mitotic defects, and eventually, cell death.
Our objective was to determine how the checkpoint disruption would affect the
determination of cell fate choices in SCC-38 cells treated with cisplatin. First, it
was confirmed, with Western blot in Dr. Aimin Peng’s lab, that caffeine, a wellcharacterized inhibitor of ATM and ATR, effectively silenced DNA damage
checkpoint signaling induced by cisplatin in SCC-38 cells, as evidenced by
impaired phosphorylation of Chk1 and Chk2 (Fig. 4.5.1). We then performed four
consecutive time lapse imaging experiments with caffeine and cisplatin treatment
and cell profile data show consistent results (Figure 4.5.2). Caffeine plus cisplatin
treatment resulted in 88% cell death in interphase, significantly higher than 51%
observed in cisplatin only treatment (P<0.001,Figure 4.5.3). However, no
significant cell death in mitosis or the second interphase following the first mitosis
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was observed between the cisplatin only and cisplatin-caffeine treatments (Fig.
4.5.3). This effect of caffeine strongly argued that checkpoint disruption directly
sensitizes cell death without either mitotic entry or accumulation of DNA damage
due to mitotic defects. To determine how much effect caffeine had on cell
behavior alone and to serve as a control, we conducted a pilot study in which
SCC-38 cells were treated with the same concentration caffeine (4 mM). As
indicated in Figure 4.5.4, caffeine did not induce cell death in SCC-38 cells. We
then compared the portions of surviving cells between groups of cisplatin alone
and cisplatin/caffeine combination treatment. As expected, caffeine abolished the
portion of interphase arrested cells (Fig. 4.5.5), presumably by suppressing the
ATM/ATR-mediated DNA damage checkpoint. To our surprise, caffeine
treatment also completely eliminated the portion of checkpoint slippage, as
essentially no cell was able to successfully complete cell division in the presence
of caffeine and cisplatin (Fig. 4.5.5). Collectively, caffeine treated SCC-38
responded to cisplatin in a manner similar to the chemosensitive HaCaT cell.
Again, our findings with live cell microscopy were confirmed in Dr. Peng’s lab that
caffeine greatly enhanced the efficacy of cisplatin in SCC-38 cells using both cell
proliferation and clonogenic assays (Fig. 4.5.6, Fig. 4.5.7).
4.6 Inhibition of ATR, but not ATM, sensitizes interphase cell death

Caffeine inhibits both ATM and ATR, the two upstream DDR kinases. It has been
well illustrated that ATM and ATR, though sharing great similarity in structural
elements and substrate recognition, respond to different types of DNA lesions
and are activated by distinct mechanisms (Shiloh 2003). To better understand
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the involvement of ATM and ATR in DNA repair mechanism, we utilized specific
inhibitors that selectively target either ATM or ATR. As discussed and confirmed
previously in Dr. Peng’s lab with Western blot, KU-55933 (ATMi) inhibited
phosphorylation of Chk2 in response to cisplatin, whereas VE-821 (ATRi)
disrupted ATR-dependent phosphorylation of Chk1 (Fig. 4.5.1).
Based on the cell profile data from four consecutive time-lapse microscopy
experiments, the results were very consistent (Fig. 4.6.1). ATM inhibition did not
significantly alter the profile of cell fate choices after cisplatin treatment (Fig.
4.6.2). For instance, on average 50% of SCC-38 cells treated with cisplatin
resulted in cell death in interphase without mitotic entry, while 45% of SCC-38
cells experienced similar fate when exposed to cisplatin-ATMi combination
(P>0.05). Moreover, 11.8% of SCC-38 cells treated with cisplatin died in the
second interphase following the first mitosis, compared to 11.5% of cancer cells
underwent similar fate in cisplatin/ATMi combination group (P>0.05). Only a
moderate induction of mitotic cell death was detected with ATM inhibition
(P=0.03, Fig. 4.6.2). In addition, we observed no difference between cisplatin
only and cisplatin/ATMi treated cells in term of cell survival via interphase arrest
(checkpoint activation) or checkpoint slippage (Fig. 4.6.3). ATR, on the other
hand, sensitized interphase cell death to approximately 70%, as compared to
50% in the group of cisplatin-treated only group(P=0.03, Fig. 4.6.2). Moreover,
ATR inhibition substantially reduced the number of cells that were arrested in
interphase or underwent checkpoint slippage (Fig. 4.6.3). The impact of ATR
inhibition on the profile of post-cisplatin cell fate resembled that of caffeine,
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suggesting that ATR, rather than ATM, plays a major role in cell fate
determination after cisplatin treatment. Our conclusion was later confirmed by the
works in Dr. Peng’s lab using cell proliferation and clonogenic assays (Fig. 4.6.4,
Fig. 4.6.5). Thus, ATR-mediated checkpoint pathway presents a promising target
to improve the therapeutic outcome using cisplatin.
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Figure 4.1.1. Time-lapse sequences of SCC-38 cell
This figure illustrates the time-lapse sequences illustrating the fates
exhibited by SCC-38 cells following prolonged exposure to cisplatin, 16
µM.
The four main behaviors of SCC-38 cells observed using time-lapse
microscope were proliferation in interphase, division, death in mitosis and
death in interphase.
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Death in interphase
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Interphase between mitosis
No mitotic entry

Cells remain in interphase without entering
mitosis

b

Cells die interphase without ever entering
mitosis

c

Cells enter mitosis, undergo division, exit then
remain in interphase for the remainder of the
experiment

d

Cells enter mitosis, undergo division, exit then die
in interphase

D
'

Cells enter mitosis, undergo division, then die in
mitosis

e

Cells enter mitosis, die in mitosis without ever
dividing

Figure 4.1.2. Profiling the cell fate choices
This figure illustrates how cell profile was constructed. Each horizontal line
represents one cell, with the length of the line corresponding to the duration of a
given behavior. The color of the line represents cell behavior.
Note, when cells exit mitosis and remain in the interphase for the remainder of
the experiment, the line ends when the cell exits mitosis.

.
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Figure 4.1.3. Diverse cell fate choices in resistant cancer cells treated
with cisplatin
As described in Methods and Materials, cell fate profiles of SCC-38 cells
treated with or without cisplatin were quantified. A representative
experiment is shown.
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Cell Behavior Distribution
Cell behavior
Control (%)
a: No mitotic entry
2.4
b: Death in interphase
5.4
c: Entering mitosis and dividing
70.4
d: Entering mitosis, dividing, death in interphase
6.0
e: Entering mitosis and death in mitosis
3.6

Cisplatin (%)
25.4
45.4
13.8
13.0
1.2

Table 4.1. Cell behavior distribution
Table showing the percentage of SCC-38 cells in each behavioral category in the control
and cisplatin treated samples. Please note: there are small percentage of cells
underwent different cell fate and are not included in this table.
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Figure 4.1.4. The induction of cell death by cisplatin in UM-SCC38 cells
The percentages of cells underwent interphase cell death without mitotic entry,
death in mitosis, or in the subsequent interphase following the first mitosis were
shown. SCC-38 cells without cisplatin treatment were included as a control.
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Figure 4.1.5. Cell cycle arrest in interphase
The percentages of cells that were arrested in interphase were shown in UMSCC-38 cells with or without cisplatin.
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Figure 4.1.6. Continuous cell proliferation
The percentages of cell that exhibited continued cell proliferation (as judged by
mitotic entry) were shown in SCC-38 cells with or without cisplatin.
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Figure 4.1.7. Time before mitotic entry
The length of interphase prior to mitotic entry was shown in the control and
cisplatin-treated SCC-38 cells.
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Figure 4.2.1. Mitotic duration of SCC-38 cells
The average amount of time, in minutes, that SCC-38 cells spent in mitosis when
treated with or without cisplatin is shown.
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Figure 4.2.2. Mitotic duration of three post-mitotic cellular behaviors
The duration of mitotic arrest, in minutes, of three different behavioral groups of
SCC-38 cells is shown.
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Figure 4.2.3. Cell fate choices of SCC-38 cells
Cell fate profiles of HNSCC-38 cells when treated with a combination of 16 µM
cisplatin and 5 µM Mg-132
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Figure 4.2.4. SCC-38 cell proliferation under the influence of drug and/or
inhibitor
The SCC-38 cells were divided into three groups and subjected to cisplatin only,
Mg-132 only, or cisplatin plus Mg-132 over a period of 4 days. The cell
proliferation in each group was measured after each day, using hemocytometer,
and the plot shows the proliferation of cells over a 4-day period. The relative cell
number compared to the actual starting number on day 1 is shown.
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Figure 4.2.5. Cologenic assay
SCC-38 cells were untreated (control), treated with cisplatin only, Mg-132 only, or
cisplatin combined with Mg-132.
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Figure 4.3.1. SCC-38 M-phase cell profile
Cell fate profiles of HNSCC-38 cells in M-phase when treated with or without
cisplatin quantified and shown.

43

Figure 4.3.2. Asynchronized and M-phase SCC-38 cell survival
The percentages of cell survival in interphase or M-phase SCC-38 cells when
treated with cisplatin.
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M-phase Cell Behavior Responding to Cisplatin Treatment
Cell Behaviors
%
f: Dividing during mitotic phase
7
g: Dividing and death in interphase
59
G’: Dividing and death in mitosis
5
h: Interphase between mitosis
0
I: Death in mitosis
29

Table 4.3. M-phase cell behavior responding to cisplatin treatment
Table shows the distributions cell death of SCC-38 cells responding to cisplatin during
M-phase.
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Figure 4.4.1. Cell fate profiles of HaCaT cells
Cell fate profiles of HaCaT cells treated with or without cisplatin quantified and
shown. A representative experiment is shown.
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Figure 4.4.2. The induction of cell death by cisplatin in SCC-38 and HaCaT
cells
The percentages of cells underwent interphase cell death without mitotic entry,
death in mitosis, or in the subsequent interphase following the first mitosis were
compared and shown between these two cell lines.
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Figure 4.4.3. Cell survival via either checkpoint activation or checkpoint
slippage
The percentages of HaCaT and SCC-38 cells that survived cisplatin treatment by
checkpoint activation and checkpoint slippage are shown.
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Figure 4.5.1. Western blotting
SCC-38 cells were treated with cisplatin, caffeine, and specific inhibitors of ATM
and ATR (ATMi and ATRi). Phosphorylation of Chk1 and Chk2, and total Chk2
are shown by immunoblotting.
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Figure 4.5.2. Cell fate choices of SCC-38 cells
Cell fate profiles of SCC-38 cells treated with cisplatin or cisplatin-caffeine
combination. The concentrations for cisplatin and Mg-132 were 16µM and 5µM,
respectively. A representative experiment is shown.

50

Figure 4.5.3. The induction of cell death by cisplatin plus caffeine in SCC-38
cells
The percentages of SCC-38 cells underwent interphase cell death without mitotic
entry, death in mitosis, or in the subsequent interphase following the first mitosis
were shown. SCC-38 cells without caffeine treatment (cisplatin only) were
included to serve as comparison.
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Figure 4.5.4. Light microscope photographs of SCC-38 cells
Images were taken of SCC-38 cells under the light microscope with or without
caffeine treatment.
As discussed in our paper, SCC-38 cells were treated with caffeine alone to
determine if caffeine had any significant behavior on cancer cells.
As evident, cell death was not significant between the two groups to warrant a
time-lapse analysis.
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Figure 4.5.5. Cell survival via checkpoint activation or checkpoint slippage
The percentages of SCC-38 cells that survived the cisplatin plus caffeine
treatment by checkpoint activation and checkpoint slippage were shown. SCC-38
cells with cisplatin only treatment were included as comparison.
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Figure 4.5.6. Cell proliferation
The SCC-38 cells were divided into three groups and subjected to cisplatin only,
caffeine only, or cisplatin plus caffeine over a period of 4 days.The cell
proliferation in each group was measured after each day, using hemocytometer,
and the plot shows the proliferation of each group of cells over a 4-day period.
The relative cell number compared to the actual starting number on day 1 is
shown.
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Figure 4.5.7. Clonogenic assay
SCC-38 cells were untreated (control), treated with cisplatin only, caffeine only,
or cisplatin combined with caffeine.
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Figure 4.6.1. Inhibition of ATR, but not ATM, sensitizes the cisplatin
treatment
SCC-38 cells were treated with cisplatin and ATM/ATR inhibitors as indicated. A
representative experiment is shown.
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Figure 4.6.2. The induction of cell death by cisplatin and ATM/ATR
inhibitors in SCC-38 cells
The percentages of cells underwent interphase cell death without mitotic entry,
death in mitosis, or in the subsequent interphase following the first mitosis were
shown.
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Figure 4.6.3. Cell survival via checkpoint activation or checkpoint slippage
The percentages of SCC-38 cells that survived cisplatin and ATM/ATR inhibitors
by checkpoint activation and checkpoint slippage.
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Figure 4.6.4. Cell proliferation
The SCC-38 cells were divided into three groups and subjected to cisplatin only,
ATRi only, or cisplatin plus ATRi over a period of 4 days.The cell proliferation in
each group was measured after each day, using hemocytometer, and the plot
shows the proliferation of each group of cells over a 4-day period. The relative
cell number compared to the actual starting number on day 1 is shown.
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Figure 4.6.5. Clonogenic assay
SCC-38 cells were untreated (control), treated with cisplatin only, ATR inhibitor
only, or cisplatin combined with ATR inhibitor.
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CHAPTER 5: DISCUSSION

The ability to quantitatively measure individual cell death with live-cell imaging
can reveal detailed information with respect to how cell fate choices are
determined. In turn, the knowledge about cell fate choices will help us
understand cancer resistance and improve treatment efficacy. In this study we
profiled SCC-38 cell behavior in responding to cisplatin treatment. SCC-38 cell
line was chosen due to its well-documented chemoresistance. Not surprisingly, a
significantly smaller portion of SCC-38 cells died after the treatment when
compared to HaCaT, a non-tumorigenic keratinocyte cell line. Interestingly, in
both SCC-38 and HaCaT lines, the majority of cell death occurred in interphase
without mitotic entry. By comparison, only small portions of cells either entered
and then died in mitosis, or completed cell division and then died in the
subsequent interphase. Analysis of the surviving SCC-38 cells revealed the coexistence of checkpoint arrest and checkpoint slippage—some surviving cells
remained arrested in interphase without mitotic entry, while another group of cells
underwent active cell division without detectable delay in either interphase or Mphase. Hence, our study revealed a complex pattern of cell fate choices in
cancer cells treated with cisplatin.
Furthermore, we examined the length of mitosis in cells that entered mitosis after
cisplatin treatment. To our surprise, cisplatin treatment did not cause prolonged
mitosis, indicating the absence of vital mitotic defects or activation of the mitotic
spindle checkpoint. In principle, cells entered mitosis after therapeutic treatment
may die in mitosis, die after mitotic exit, or complete mitosis and survive. As
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reported in this study, all these choices existed in cisplatin-treated SCC-38 cells.
We then further investigated if the duration of mitosis would predict cell death or
survival in the subsequent interphase. However, no significant difference was
observed in the length of mitosis regardless of the cell fate after mitotic exit; as
post-mitotic cell death and survival groups spent 40 and 39 minutes, respectively,
in mitotic phase. Very interestingly, we found that the small portion of cisplatintreated cells entered, and then died in mitosis typically spent more than 2 hours
in mitosis prior to cell death. This association between the prolonged mitotic
progression and mitotic cell death prompted us to examine the effect of delaying
mitotic exit. We showed a surprisingly strong synergy between cisplatin and Mg132, a proteasome inhibitor that was known to suppress mitotic exit. Thus, our
study suggested a promising strategy of combinatorial therapy using cisplatin
and Mg-132, which shall be further evaluated in laboratory or clinical studies.
Similar to interphase cells, SCC-38 cells exposed to cisplatin during mitosis
exhibited diverse cell fates. However, the pattern of cell fate choices differed
remarkably. Collectively, mitotic cells were more sensitive to cisplatin, and the
majority of these cells died in mitosis or after mitotic exit. Thus, in addition to
blocking DNA replication and transcription, our findings suggested cisplatininduced DNA damage also interfered with mitotic progression. Moreover, recent
studies showed that the molecular pathways of DNA repair and DNA damage
checkpoint are largely silenced during mitosis (Heijink et al 2013; Giunta et al
2010). It has been also suggested that the mitotic suppression of DNA repair is
beneficial as mitotic DNA repair may lead to chromosomal instability, e.g., via
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telomere fusion (Orthwein et al 2014). Therefore, the hypersensitivity to DNA
damage is a desirable choice for mitotic cells that lack the capability of DNA
repair.
Since DDR plays a key role in cell fate determination after DNA damage, it has
been proposed that targeting the DDR may offer a powerful tool to overcome
chemoresistance. In supporting of this notion, we found that SCC-38 cells treated
with caffeine, an inhibitor of ATM and ATR, exhibited greatly enhanced cell death
during cisplatin treatment. Contrary to the common assumption that checkpoint
disruption would lead to cell death by allowing mitotic entry with DNA damage,
our study showed that caffeine-cisplatin treatment almost exclusively induced cell
death in interphase without mitotic entry. As expected, caffeine suppressed
checkpoint activation after cisplatin treatment, and abolished the portion of cell
survival via interphase arrest. Moreover, and perhaps counterintuitively, caffeine
treatment also eliminated the portion of checkpoint slippage. Therefore, we
speculate that caffeine may prevent checkpoint slippage at least partially by
suppressing DNA repair, as supported by several recent studies (Zelensky et al
2013; Tsabar et al 2015; Sabisz and Skladanowski 2008)
In addition to inhibit ATM and ATR simultaneously using caffeine, we further
advanced the study using inhibitors that specifically target either one of these
kinases. Similar to caffeine, ATR inhibition reduced cell survival by preventing
checkpoint arrest and checkpoint slippage, and enhancing cell death in
interphase. By comparison, ATM inhibition exhibited no significant effect on cell
death or survival. Therefore, the effect of caffeine in sensitizing the cisplatin
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treatment is largely conferred through ATR inhibition. However, it should be
noted that the effect of ATR inhibition appeared less profound compared to that
of caffeine, which implies additional targets of caffeine, as suggested previously
(Cortez 2003).
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CHAPTER 6: CONCLUSION

The diverse cell fate choices of SCC-38 and HaCaT cells were confirmed
using live cell imaging. Our results showed the majority of cell death occurred in
interphase without mitotic entry and a significantly smaller portion of SCC-38
cells died after the cisplatin treatment when compared to HaCaT. On the other
hand, analysis of the surviving SCC-38 cells revealed the co-existence of
checkpoint arrest and checkpoint slippage. However, caffeine was shown to
abolish these surviving mechanisms in cisplatin treated cells since essentially no
cells were able to survive cisplatin/caffeine treatment. Moreover, our
combination therapy of cisplatin plus MG-132 showed strong synergistic effect on
SCC-38 cell death. And, inhibition of ATR, instead of ATM, may be a more
promising pathway to improve therapeutic outcome of cisplatin treatment.
Overall, our study revealed new insights into chemoresistance and suggested
combinatorial strategies that potentially overcome cancer resistance.
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